{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Barrdahl M"],"funding":["Intramural NIH HHS","US National Institutes of Health","Cancer Research UK","Stavros Niarchos Foundation","Hellenic Health Foundation","Medical Research Council","National Institute for Health Research (NIHR)","National Cancer Institute","NCI NIH HHS","Department of Defense Prostate Cancer Research Program Fellowship","National Breast Cancer Foundation","Intramural Research Program of National Institutes of Health and National Cancer Institute, Division of Cancer Epidemiology and Genetics"],"pagination":["2837-45"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4615576"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["137(12)"],"pubmed_abstract":["The survival of breast cancer patients is largely influenced by tumor characteristics, such as TNM stage, tumor grade and hormone receptor status. However, there is growing evidence that inherited genetic variation might affect the disease prognosis and response to treatment. Several lines of evidence suggest that alleles influencing breast cancer risk might also be associated with breast cancer survival. We examined the associations between 35 breast cancer susceptibility loci and the disease over-all survival (OS) in 10,255 breast cancer patients from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3) of which 1,379 died, including 754 of breast cancer. We also conducted a meta-analysis of almost 35,000 patients and 5,000 deaths, combining results from BPC3 and the Breast Cancer Association Consortium (BCAC) and performed in silico analyses of SNPs with significant associations. In BPC3, the C allele of LSP1-rs3817198 was significantly associated with improved OS (HRper-allele =0.70; 95% CI: 0.58-0.85; ptrend  = 2.84 × 10(-4) ; HRheterozygotes  = 0.71; 95% CI: 0.55-0.92; HRhomozygotes  = 0.48; 95% CI: 0.31-0.76; p2DF  = 1.45 × 10(-3) ). In silico, the C allele of LSP1-rs3817198 was predicted to increase expression of the tumor suppressor cyclin-dependent kinase inhibitor 1C (CDKN1C). In the meta-analysis, TNRC9-rs3803662 was significantly associated with increased death hazard (HRMETA =1.09; 95% CI: 1.04-1.15; ptrend  = 6.6 × 10(-4) ; HRheterozygotes  = 0.96 95% CI: 0.90-1.03; HRhomozygotes  = 1.21; 95% CI: 1.09-1.35; p2DF =1.25 × 10(-4) ). In conclusion, we show that there is little overlap between the breast cancer risk single nucleotide polymorphisms (SNPs) identified so far and the SNPs associated with breast cancer prognosis, with the possible exceptions of LSP1-rs3817198 and TNRC9-rs3803662."],"journal":["International journal of cancer"],"pubmed_title":["Association of breast cancer risk loci with breast cancer survival."],"pmcid":["PMC4615576"],"funding_grant_id":["G1000143","U01 CA164973","U01-CA98233-07, U01-CA98710-06, U01-CA98216-06 and U01-CA98758-07","UM1 CA182913","NF-SI-0512-10114","U01 CA098233","U01 CA098710","U01-CA98233-07","U01-CA98758-07","P30 CA071789","U01-CA98216-06","U01 CA098758","U01 CA098216","U01-CA98710-06","G0401527","14136","IF-12-06"],"pubmed_authors":["Diver WR","Southey MC","Peeters PH","Kaaks R","Hunter DJ","Khaw KT","Trichopoulos D","Le Marchand L","Weiderpass E","Hoover RN","Gapstur SM","Barrdahl M","Giles GG","Gunter M","Shui I","Chanock SJ","Milne RL","Sund M","Overvad K","Sanchez MJ","Joshi AD","Willett W","Buring JE","Gaudet MM","Haiman C","Ziegler RG","Black A","Panico S","Lindstrom S","Henderson BE","Lee IM","Dossus L","Kraft P","Hankinson S","Canzian F","Campa D"],"additional_accession":[]},"is_claimable":false,"name":"Association of breast cancer risk loci with breast cancer survival.","description":"The survival of breast cancer patients is largely influenced by tumor characteristics, such as TNM stage, tumor grade and hormone receptor status. However, there is growing evidence that inherited genetic variation might affect the disease prognosis and response to treatment. Several lines of evidence suggest that alleles influencing breast cancer risk might also be associated with breast cancer survival. We examined the associations between 35 breast cancer susceptibility loci and the disease over-all survival (OS) in 10,255 breast cancer patients from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3) of which 1,379 died, including 754 of breast cancer. We also conducted a meta-analysis of almost 35,000 patients and 5,000 deaths, combining results from BPC3 and the Breast Cancer Association Consortium (BCAC) and performed in silico analyses of SNPs with significant associations. In BPC3, the C allele of LSP1-rs3817198 was significantly associated with improved OS (HRper-allele =0.70; 95% CI: 0.58-0.85; ptrend  = 2.84 × 10(-4) ; HRheterozygotes  = 0.71; 95% CI: 0.55-0.92; HRhomozygotes  = 0.48; 95% CI: 0.31-0.76; p2DF  = 1.45 × 10(-3) ). In silico, the C allele of LSP1-rs3817198 was predicted to increase expression of the tumor suppressor cyclin-dependent kinase inhibitor 1C (CDKN1C). In the meta-analysis, TNRC9-rs3803662 was significantly associated with increased death hazard (HRMETA =1.09; 95% CI: 1.04-1.15; ptrend  = 6.6 × 10(-4) ; HRheterozygotes  = 0.96 95% CI: 0.90-1.03; HRhomozygotes  = 1.21; 95% CI: 1.09-1.35; p2DF =1.25 × 10(-4) ). In conclusion, we show that there is little overlap between the breast cancer risk single nucleotide polymorphisms (SNPs) identified so far and the SNPs associated with breast cancer prognosis, with the possible exceptions of LSP1-rs3817198 and TNRC9-rs3803662.","dates":{"release":"2015-01-01T00:00:00Z","publication":"2015 Dec","modification":"2024-10-18T00:11:15.811Z","creation":"2019-03-27T02:00:33Z"},"accession":"S-EPMC4615576","cross_references":{"pubmed":["25611573"],"doi":["10.1002/ijc.29446"]}}